COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Advancing Proteomics Research through Collaboration

The National Cancer Institute (NCI), through the Office of Cancer Clinical Proteomics Research (OCCPR), has signed two Memorandums of Understanding (MOUs) in the areas of sharing proteomics reagents and protocols and also in regulatory science.

Sharing Reagents and Protocols in Oncology and Cardiovascular Research

A recently signed MOU with the Proteomics Center Program of the National Heart, Lung, and Blood Institute (NHLBI) extends formal scientific and programmatic collaborations between NCI's OCCPR and NHLBI in the science of proteomics. The cooperation is intended to develop new research activities [through the sharing of reagents, protocols; and bioinformatics standards development] in using proteomic technologies to advance our understanding of the intricate biology of cancer, cardiovascular and lung diseases.

Proteomics Regulatory Science

The understanding of how the regulatory agency (U.S. Food and Drug Administration - FDA) reviews assay clearance/approval requests by a sponsor is extremely important to translational science, especially as it pertains to emerging technologies/platforms. The NCI and the FDA, sister agencies within the Department of Health and Human Services, have formally extended their scientific and programmatic collaborations through a MOU between OCCPR and Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD). This MOU represents a commitment in supporting the development of proteomics science and technology development and applications, such as statistical experimental design, instrument analytical validation, informatics, and biospecimen sample preparation, as they pertain to clinical cancer diagnostics and cancer therapeutics development.

For more information about OCCPR visit